CXCR4 blockade reduces the severity of murine heart allograft rejection by plasmacytoid dendritic cell-mediated immune regulation

Allograft-specific regulatory T cells (T-reg cells) are crucial for long-term graft acceptance after transplantation. Although adoptive T-reg cell transfer has been proposed, major challenges include graft-specificity and stability. Thus, there is an unmet need for the direct induction of graft-specific T-reg cells. We hypothesized a synergism of the immunotolerogenic effects of rapamycin (mTOR inhibition) and plerixafor (CXCR4 antagonist) for T-reg cell induction. Thus, we performed fully-mismatched heart transplantations and found combination treatment to result in prolonged allograft survival. Moreover, fibrosis and myocyte lesions were reduced. Although less CD3(+) T cell infiltrated, higher T-reg cell numbers were observed. Noteworthy, this was accompanied by a plerixafor-dependent plasmacytoid dendritic cells-(pDCs)-mobilization. Furthermore, in vivo pDC-depletion abrogated the plerixafor-mediated T-reg cell number increase and reduced allograft survival. Our pharmacological approach allowed to increase T-reg cell numbers due to pDC-mediated immune regulation. Therefore pDCs can be an attractive immunotherapeutic target in addition to plerixafor treatment.

Automated summary

The study demonstrated that the combination of rapamycin and plerixafor in a fully-mismatched heart transplant model resulted in prolonged allograft survival, reduced fibrosis and myocyte lesions, and increased T-reg cell numbers, possibly through the regulation of pDCs. This pharmacological approach highlights the potential of pDCs as an attractive immunotherapeutic target along with plerixafor treatment.